Table 1.
General characteristics of studies included in the meta-analysis.
| Author | Year | Language | Country | Diagnostic criteria | Source of control | Sample size (case/control) | Method | Genotype | HWE | NOS | Ref | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case | Control | |||||||||||||||||||
| G | A | GG | GA | AA | G | A | GG | GA | AA | |||||||||||
| Bu | 2014 | English | China | IDF | HB | 200/200 | RFLP | 351 | 49 | 162 | 27 | 11 | 384 | 16 | 188 | 8 | 4 | Yes | 7 | 20 |
| Uzma | 2019 | English | Pakistan | IDF | HB | 224/200 | RFLP | 301 | 147 | 100 | 101 | 23 | 280 | 120 | 102 | 76 | 22 | Yes | 8 | 21 |
| Vani | 2012 | English | India | NCEPATP III | HB | 269/272 | RFLP | 429 | 109 | 169 | 91 | 9 | 502 | 42 | 230 | 42 | 0 | Yes | 6 | 22 |
| Zhao | 2013 | Chinese | China | NCEPATP III | HB | 600/600 | Taqman | 1083 | 117 | 488 | 107 | 5 | 1142 | 58 | 543 | 56 | 1 | Yes | 7 | 23 |
| Catherine | 2010 | English | France | NCEPATP III | PB | 877/877 | Golden Gate Assay | 1549 | 205 | 683 | 183 | 11 | 1494 | 260 | 635 | 224 | 18 | Yes | 6 | 24 |
| Ranbir | 2012 | English | India | NCEPATP III | HB | 245/321 | RFLP | 236 | 254 | 11 | 214 | 20 | 343 | 299 | 56 | 231 | 34 | Yes | 8 | 25 |
| Aline | 2005 | English | France | NCEPATP III | PB | 601/594 | RFLP | 496 | 79 | 198 | 73 | 3 | 1409 | 269 | 599 | 211 | 29 | Yes | 7 | 26 |
| Gong | 2016 | Chinese | China | CDS | HB | 119/60 | RFLP | 204 | 34 | 89 | 26 | 4 | 111 | 9 | 51 | 9 | 0 | Yes | 7 | 27 |
| Fan | 2019 | Chinese | China | CDS | HB | 48/60 | RFLP | 81 | 15 | 35 | 11 | 2 | 113 | 7 | 53 | 7 | 0 | Yes | 8 | 28 |
| Seyed | 2015 | English | Iran | IDF | HB | 94/128 | RFLP | 122 | 66 | 41 | 40 | 20 | 168 | 88 | 60 | 48 | 20 | Yes | 7 | 29 |
| Szkup | 2018 | English | Poland | IDF | PB | 118/298 | Melting curves | 201 | 35 | 85 | 31 | 2 | 515 | 81 | 226 | 63 | 9 | Yes | 8 | 30 |
HB hospital based, PB population based, IDF the International Diabetes Federation, NCEPATP III the National Cholesterol Education Program Adult Treatment Panel III, HWE Hardy–Weinberg Equilibrium, CDS Chinese Diabetes Society, RFLP restriction fragment length polymorphism, NOS Newcastle–Ottawa Score.